NCT07140679 2025-09-25
Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer
Emory University
Phase 2 Recruiting
Emory University
Centre Hospitalier Universitaire de Besancon
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Cancer Institute (NCI)